LabCorp

Labcorp has partnered with Roche to implement FDA-cleared VENTANA DP 600 and DP 200 slide scanners, enabling pathologists to diagnose patients using digital images instead of traditional microscopes.

Labcorp has completed its acquisition of BioReference Health's oncology and oncology-related clinical testing services across the United States for up to $225 million.

Mercy BioAnalytics closed a $59 million Series B financing round co-led by Novalis and Sozo Ventures to advance its extracellular vesicle-based liquid biopsy platform for early cancer detection.

Vor Bio has appointed Dr. Qing Zuraw as Chief Development Officer, bringing over 25 years of experience in autoimmune disease clinical development.

Quanterix Corporation has completed its acquisition of Akoya Biosciences, establishing a scaled leader in early disease detection for neurology, oncology, and immunology markets.

RetinalGenix Technologies has entered into an agreement with LabCorp to support the rollout of its DNA/RNA/GPS Pharmaco-Genetic Mapping platform for early detection of ocular and systemic diseases.

GeneCentric Therapeutics closed an $8 million Series C financing round led by Hatteras Venture Partners to commercialize its GenomicsNext platform, which combines gene expression analysis with DNA variant detection in liquid biopsies.

Predictive Oncology has successfully developed two distinct 3D liver toxicity models exclusively for Labcorp, including human and rat models that represent the liver microenvironment for drug metabolism and toxicity evaluation.

Teal Health's Teal Wand has received FDA approval as the first at-home cervical cancer screening test, offering an alternative to in-clinic pap smears for women aged 25-65 at average risk.

CND Life Sciences has raised $13.5 million in Series A financing, with $8.6 million from its recent Series A3 round, to expand access to its Syn-One Test for detecting neurodegenerative diseases.